Pharma BD Deal Intelligence

Shionogi & Co., Ltd. / IntraBio Inc.

2026 · Acquisition/Merger · $2.0B · Pending

On October 5, 2026 Shionogi & Co., Ltd. announced that its board had approved an agreement for its U.S. subsidiary Shionogi Inc. to acquire all shares of IntraBio Inc., a biopharmaceutical company focused on neurodegenerative disease, for a reported approximately $2.0 billion. The transaction transfers worldwide intellectual property and commercialization rights to AQNEURSA (levacetylleucine), approved by FDA in September 2024 for the neurological manifestations of Niemann-Pick disease type C and by the EMA in January 2026. On September 18, 2026 FDA granted a supplemental approval making AQNEURSA the first and only therapy approved for ataxia in patients with Ataxia-Telangiectasia. IntraBio becomes a wholly owned subsidiary of Shionogi Inc.; closing is expected between November and December 2026. The deal follows Shionogi's earlier 2026 acquisition of global rights to an ALS asset from Tanabe Pharma.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Shionogi & Co., Ltd. deals